Pharming: 3 Key Takeaways for Long-Term Investors

PHAR posted Q3 2026 revenue of $117.6 million, up 21%, while operating profit jumped 89% to $29.9 million. Profit growing far faster than sales signals meaningful operating leverage in the quarter.

RUCONEST, the company's core rare disease product, stabilized demand. Joenja grew 58%, driven by geographic and pediatric expansion, and appears to be the main engine behind the top-line gain. Interpretation: with RUCONEST holding steady rather than expanding, Joenja's trajectory likely carries most of the growth story from here.

The balance sheet adds support. Pharming holds $191 million in cash and says it needs no external financing. For investors who worry about dilution in small-cap biotech, that removes a common overhang. Management is also advancing its clinical pipeline into larger immunodeficiency markets, which would widen the addressable opportunity beyond the current rare disease footprint.

Interpretation: an 89% profit surge paired with a self-funded pipeline pushes PHAR toward a profitable-grower profile instead of a cash-burn story. That shift can change how the market prices the shares, though the source gives no valuation data to test it.